Bioengineered stem cells in neural development and neurodegeneration research

Ageing Research Reviews

Volumn 12, Issue 3, 2013, Pages 739-748

  Yuan, Shauna H ^a   Shaner, Mason ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Human disease model; Neural development; Neurodegeneration; Stem cells; Transplantation

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; HUNTINGTIN;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ASTROCYTE; AUTISM; BIOENGINEERING; CAG REPEAT; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DRUG SCREENING; EMBRYONIC STEM CELL; FIBROBLAST; GENE; HUMAN; HUMAN CELL; HUMAN DEVELOPMENT; HUNTINGTON CHOREA; IN VITRO STUDY; MACHADO JOSEPH DISEASE; MOUSE; NERVE CELL; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NEURAL STEM CELL; NONHUMAN; PARKINSON DISEASE; PERSONALIZED MEDICINE; PHENOTYPE; PLURIPOTENT STEM CELL; RESEARCH; RETT SYNDROME; REVIEW; SCHIZOPHRENIA; SOMATIC CELL; SPINOCEREBELLAR DEGENERATION; STEM CELL TRANSPLANTATION; SYNAPSE;

HUMAN DISEASE MODEL; NEURAL DEVELOPMENT; NEURODEGENERATION; STEM CELLS; TRANSPLANTATION;

AGING; ANIMALS; BIOENGINEERING; CELL TRANSDIFFERENTIATION; HUMANS; NEURAL STEM CELLS; NEURODEGENERATIVE DISEASES; NEURONS; PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION;

EID: 84881541619     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2013.04.002     Document Type: Review

References (65)

1. Aasen T., Raya A., Barrero M.J., Garreta E., Consiglio A., Gonzalez F., Vassena R., Bilic J., Pekarik V., Tiscornia G., et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nature Biotechnology 2008, 26:1276-1284.
2. Almad A.A., Maragakis N.J. Glia: an emerging target for neurological disease therapy. Stem Cell Res Ther 2012, 3:37.
3. Ambasudhan R., Talantova M., Coleman R., Yuan X., Zhu S., Lipton S.A., Ding S. Direct reprogramming of adult human fibroblasts to functional neurons under defined conditions. Cell Stem Cell 2011, 9:113-118.
4. An M.C., Zhang N., Scott G., Montoro D., Wittkop T., Mooney S., Melov S., Ellerby L.M. Genetic correction of huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 2012, 11:253-263.
5. Aoi T., Yae K., Nakagawa M., Ichisaka T., Okita K., Takahashi K., Chiba T., Yamanaka S. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 2008, 321:699-702.
6. Bateman R.J., Xiong C., Benzinger T.L., Fagan A.M., Goate A., Fox N.C., Marcus D.S., Cairns N.J., Xie X., Blazey T.M., et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. New England Journal of Medicine 2012, 367:795-804.
7. Blurton-Jones M., Kitazawa M., Martinez-Coria H., Castello N.A., Muller F.J., Loring J.F., Yamasaki T.R., Poon W.W., Green K.N., LaFerla F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:13594-13599.
8. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 1991, 82:239-259.
9. Braak H., Del Tredici K. Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 2008, 70:1916-1925.
10. Cataldo A., Rebeck G.W., Ghetri B., Hulette C., Lippa C., Van Broeckhoven C., van Duijn C., Cras P., Bogdanovic N., Bird T., et al. Endocytic disturbances distinguish among subtypes of Alzheimer's disease and related disorders. Annals of Neurology 2001, 50:661-665.
11. Chailangkarn T., Acab A., Muotri A.R. Modeling neurodevelopmental disorders using human neurons. Current Opinion in Neurobiology 2012, 22:785-790.
12. Choi J., Costa M.L., Mermelstein C.S., Chagas C., Holtzer S., Holtzer H. MyoD converts primary dermal fibroblasts, chondroblasts, smooth muscle, and retinal pigmented epithelial cells into striated mononucleated myoblasts and multinucleated myotubes. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:7988-7992.
13. Clement A.M., Nguyen M.D., Roberts E.A., Garcia M.L., Boillee S., Rule M., McMahon A.P., Doucette W., Siwek D., Ferrante R.J., et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003, 302:113-117.
14. Del Tredici K., Rub U., De Vos R.A., Bohl J.R., Braak H. Where does parkinson disease pathology begin in the brain?. Journal of Neuropathology and Experimental Neurology 2002, 61:413-426.
15. Di Giorgio F.P., Boulting G.L., Bobrowicz S., Eggan K.C. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell 2008, 3:637-648.
16. Di Giorgio F.P., Carrasco M.A., Siao M.C., Maniatis T., Eggan K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nature Neuroscience 2007, 10:608-614.
17. Ebert A.D., Liang P., Wu J.C. Induced pluripotent stem cells as a disease modeling and drug screening platform. Journal of Cardiovascular Pharmacology 2012, 60:408-416.
18. Eiges R., Urbach A., Malcov M., Frumkin T., Schwartz T., Amit A., Yaron Y., Eden A., Yanuka O., Benvenisty N., et al. Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell 2007, 1:568-577.
19. Eiraku M., Watanabe K., Matsuo-Takasaki M., Kawada M., Yonemura S., Matsumura M., Wataya T., Nishiyama A., Muguruma K., Sasai Y. Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals. Cell Stem Cell 2008, 3:519-532.
20. Elden A.C., Kim H.J., Hart M.P., Chen-Plotkin A.S., Johnson B.S., Fang X., Armakola M., Geser F., Greene R., Lu M.M., et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010, 466:1069-1075.
21. Gaspard N., Bouschet T., Hourez R., Dimidschstein J., Naeije G., van den Ameele J., Espuny-Camacho I., Herpoel A., Passante L., Schiffmann S.N., et al. An intrinsic mechanism of corticogenesis from embryonic stem cells. Nature 2008, 455:351-357.
22. Grskovic M., Javaherian A., Strulovici B., Daley G.Q. Induced pluripotent stem cells-Opportunities for disease modelling and drug discovery. Nature Reviews Drug Discovery 2011, 10:915-929.
23. Han D.W., Tapia N., Hermann A., Hemmer K., Hiing S., Araijzo-Bravo M.J., Zaehres H., Wu G., Frank S., Moritz S., et al. Direct reprogramming of fibroblasts into neural stem cells by defined factors. Cell Stem Cell 2012, 10:465-472.
24. Hanna J., Markoulaki S., Schorderet P., Carey B.W., Beard C., Wernig M., Creyghton M.P., Steine E.J., Cassady J.P., Foreman R., et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 2008, 133:250-264.
25. Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H.C., Riemenschneider M., Deyn P.P.D., Bancher C., Cras P., Wiltfang J., Mehta P.D., et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999, 52:1555-1562.
26. Israel M.A., Yuan S.H., Bardy C., Reyna S.M., Mu Y., Herrera C., Hefferan M.P., Van Gorp S., Nazor K.L., Boscolo F.S. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 2012, 482:216-220.
27. Kim J., Efe J.A., Zhu S., Talantova M., Yuan X., Wang S., Lipton S.A., Zhang K., Ding S., et al. Direct reprogramming of mouse fibroblasts to neural progenitors. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:7838-7843.
28. Kim J., Lengner C.J., Kirak O., Hanna J., Cassady J.P., Lodato M.A., Wu S., Faddah D.A., Steine E.J., Gao Q., et al. Reprogramming of postnatal neurons into induced pluripotent stem cells by defined factors. Stem Cells 2011, 29:992-1000.
29. Koch P., Breuer P., Peitz M., Jungverdorben J., Kesavan J., Poppe D., Doerr J., Ladewig J., Mertens J., Tuting T., et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature 2011, 480:543-546.
30. Kriks S., Shim J.-W., Piao J., Ganat Y.M., Wakeman D.R., Xie Z., Carrillo-Reid L., Auyeung G., Antonacci C., Buch A., et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 2011, 480:547-551.
31. Kunkanjanawan T., Noisa P., Parnpai R. Modeling neurological disorders by human induced pluripotent stem cells. Journal of Biomedicine and Biotechnology 2011, 2011:2011.
32. Lee G., Ramirez C.N., Kim H., Zeltner N., Liu B., Radu C., Bhinder B., Kim Y.J., Choi I.Y., Mukherjee-Clavin B., et al. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nature Biotechnology 2012, 30:1244-1248.
33. Lepore A.C., O'Donnell J., Kim A.S., Williams T., Tuteja A., Rao M.S., Kelley L.L., Campanelli J.T., Maragakis N.J. Human glial-restricted progenitor transplantation into cervical spinal cord of the SOD1 mouse model of ALS. PLoS One 2011, 6:e25968.
34. Lepore A.C., Rauck B., Dejea C., Pardo A.C., Rao M.S., Rothstein J.D., Maragakis N.J. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nature Neuroscience 2008, 11:1294-1301.
35. Lindvall O., Björklund A. Cell therapy in Parkinson's disease. Neurotherapeutics 2004, 1:382-393.
36. Liu G.-H., Barkho B.Z., Ruiz S., Diep D., Qu J., Yang S.-L., Panopoulos A.D., Suzuki K., Kurian L., Walsh C., et al. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 2011, 472:221-225.
37. Lujan E., Chanda S., Ahlenius H., Sudhof T.C., Wernig M. Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:2527-2532.
38. Marchetto M.C., Muotri A.R., Mu Y., Smith A.M., Cezar G.G., Gage F.H. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell 2008, 3:649-657.
39. Marchetto M.C.N., Carromeu C., Acab A., Yu D., Yeo G.W., Mu Y., Chen G., Gage F.H., Muotri A.R. A model for neural development and treatment of rett syndrome using human induced pluripotent stem cells. Cell 2010, 143:527-539.
40. Muotri A.R., Nakashima K., Toni N., Sandler V.M., Gage F.H. Development of functional human embryonic stem cell-derived neurons in mouse brain. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:18644-18648.
41. Murray M.E., Graff-Radford N.R., Ross O.A., Petersen R.C., Duara R., Dickson D.W. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurology 2011, 10:785-796.
42. Nakano T., Ando S., Takata N., Kawada M., Muguruma K., Sekiguchi K., Saito K., Yonemura S., Eiraku M., Sasai Y. Self-formation of optic cups and storable stratified neural retina from human ESCs. Cell Stem Cell 2012, 10:771-785.
43. Pang Z.P., Yang N., Vierbuchen T., Ostermeier A., Fuentes D.R., Yang T.Q., Citri A., Sebastiano V., Marro S., Sudhof T.C., et al. Induction of human neuronal cells by defined transcription factors. Nature 2011, 476:220-223.
44. Park I.-H., Arora N., Huo H., Maherali N., Ahfeldt T., Shimamura A., Lensch M.W., Cowan C., Hochedlinger K., Daley G.Q. Disease-specific induced pluripotent stem cells. Cell 2008, 134:877-886.
45. Peng J., Liu Q., Rao M.S., Zeng X. Using human pluripotent stem cell-derived dopaminergic neurons to evaluate candidate Parkinson's disease therapeutic agents in MPP+ and rotenone models. Journal of Biomolecular Screening 2013.
46. Politis M., Wu K., Loane C., Quinn N.P., Brooks D.J., Oertel W.H., Bjorklund A., Lindvall O., Piccini P. Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Science Translational Medicine 2012, 4:128ra141.
47. Qiang L., Fujita R., Yamashita T., Angulo S., Rhinn H., Rhee D., Doege C., Chau L., Aubry L., Vanti W.B., et al. Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons. Cell 2011, 146:359-371.
48. Ring K.L., Tong L.M., Balestra M.E., Javier R., Andrews-Zwilling Y., Li G., Walker D., Zhang W.R., Kreitzer A.C., Huang Y. Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell Stem Cell 2012, 11:100-109.
49. Rovelet-Lecrux A., Frebourg T., Tuominen H., Majamaa K., Campion D., Remes A.M. APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage. Journal of Neurology, Neurosurgery and Psychiatry 2007, 78:1158-1159.
50. Sheridan S.D., Theriault K.M., Reis S.A., Zhou F., Madison J.M., Daheron L., Loring J.F., Haggarty S.J. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS One 2011, 6:e26203.
51. Shi Y., Kirwan P., Smith J., MacLean G., Orkin S.H., Livesey F.J. A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Science Translational Medicine 2012, 4:124ra129.
52. Slack J.M.W. Metaplasia and transdifferentiation: from pure biology to the clinic. Nature Reviews Molecular Cell Biology 2007, 8:369-378.
53. Stadtfeld M., Apostolou E., Akutsu H., Fukuda A., Follett P., Natesan S., Kono T., Shioda T., Hochedlinger K. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 2010, 465:175-181.
54. Stadtfeld M., Brennand K., Hochedlinger K. Reprogramming of pancreatic β cells into induced pluripotent stem cells. Current Biology 2008, 18:890-894.
55. Tabar V., Panagiotakos G., Greenberg E.D., Chan B.K., Sadelain M., Gutin P.H., Studer L. Migration and differentiation of neural precursors derived from human embryonic stem cells in the rat brain. Nature Biotechnology 2005, 23:601-606.
56. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
57. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
58. The HD iPSC Consortium Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 2012, 11:264-278.
59. Thier M., Wirsdirfer P., Lakes Y.B., Gorris R., Herms S., Opitz T., Seiferling D., Quandel T., Hoffmann P., Nithen M.M., et al. Direct conversion of fibroblasts into stably expandable neural stem cells. Cell Stem Cell 2012, 10:473-479.
60. Urbach A., Bar-Nur O., Daley G.Q., Benvenisty N. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 2010, 6:407-411.
61. Vierbuchen T., Ostermeier A., Pang Z.P., Kokubu Y., Sudhof T.C., Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010, 463:1035-1041.
62. Xie H., Ye M., Feng R., Graf T. Stepwise reprogramming of B cells into macrophages. Cell 2004, 117:663-676.
63. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
64. Yuan S.H., Martin J., Elia J., Flippin J., Paramban R.I., Hefferan M.P., Vidal J.G., Mu Y., Killian R.L., Israel M.A., et al. Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS One 2011, 6:e17540.
65. Zhou Q., Brown J., Kanarek A., Rajagopal J., Melton D.A. In vivo reprogramming of adult pancreatic exocrine cells to [bgr]-cells. Nature 2008, 455:627-632.